Connect with us

Technology

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers

Published

on

Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics’ iDFU program

SARASOTA, Fla., June 25, 2026 /PRNewswire/ — Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has accepted the position of Study Chair for the Company’s Phase 2a clinical trial evaluating Nu-3 for the treatment of infected diabetic foot ulcers (iDFUs). Dr. Armstrong will also serve as a Scientific Advisor to Lakewood-Amedex Biotherapeutics on the iDFU program.

Dr. Armstrong is internationally recognized as one of the world’s foremost experts in diabetic foot care, including infection control, wound healing and limb preservation. Throughout his distinguished career, he has authored hundreds of peer-reviewed scientific publications and has helped shape modern approaches to preventing amputations and improving outcomes for patients with diabetes-related complications.

“We are honored to welcome Dr. Armstrong as Study Chair for our Phase 2a trial and as a Scientific Advisor to Lakewood-Amedex Biotherapeutics,” said Thomas Balzer, M.D., Ph.D., Chief Medical Officer of Lakewood-Amedex Biotherapeutics. “Dr. Armstrong’s unparalleled experience as both a surgeon and investigator in national and international clinical trials brings an important perspective to the study and our advancement of Bisphosphocin® antimicrobials. We look forward to working closely with him to evaluate the potential of Nu-3 and to further our understanding of how our novel topical antimicrobial therapies may help address persistent challenges in diabetic foot infection management.”

As Study Chair, Dr. Armstrong will provide scientific leadership and oversight for the Phase 2a study, helping guide the clinical evaluation of Nu-3, Lakewood-Amedex Biotherapeutics’ lead Bisphosphocin® antimicrobial candidate. The Phase 2a clinical trial is a proof-of-concept study designed to evaluate the safety and efficacy of topical Nu-3 gel in patients with infected diabetic foot ulcers. The study will evaluate three dose concentrations of Nu-3 (2%, 5% and 10%) and is intended to support advancement into a larger Phase 2b clinical study.

“Infected diabetic foot ulcers are a significant clinical challenge despite advances in wound care and limb preservation, and antibiotic resistance is a potentially grave concern in this patient population,” said Dr. Armstrong. “There remains a substantial need for new therapeutic approaches that can effectively address infection while supporting healing and minimizing the risk of developing resistance. A topical antimicrobial such as Nu-3 fits well with the ongoing evolution of diabetic foot ulcer management, and if clinical studies demonstrate its effectiveness, it has the potential to help address an important treatment gap for patients suffering from these serious infections. I look forward to working with Lakewood-Amedex Biotherapeutics to evaluate the potential of this novel therapeutic approach.”

About David G. Armstrong, DPM, M.D., Ph.D.
David G. Armstrong, DPM, M.D., Ph.D., is Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC and a globally recognized leader in diabetic foot care, wound healing and limb preservation. His research and clinical work have focused on preventing amputations and improving outcomes for patients with diabetes-related complications. Dr. Armstrong has authored hundreds of peer-reviewed scientific publications and is widely regarded as one of the most influential voices in the field of diabetic foot disease and limb preservation.

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class – to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.’s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company’s SEC filings, including under “Risk Factors.” Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-world-renowned-expert-david-g-armstrong-md-phd-as-study-chair-for-phase-2a-trial-of-nu-3-in-infected-diabetic-foot-ulcers-302809879.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.

Continue Reading

Technology

Club Offers for Travel Enthusiasts in Canada

Published

on

By

TORONTO, Oct 23, 2026 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces three of many new Club Offers for Club Members in Canada.

Rigorously vetted and negotiated for us travel enthusiasts:

$799—COSTA RICA WEEK WITH FLIGHTS & CAR
We think fall is an ideal time to visit Costa Rica; the scenery is lush and the crowds are gone. Drive between volcanic Arenal and the idyllic beaches of Tamarindo on this seven-night trip. Since it’s not as busy, we were able to negotiate a price that saves members up to $648 on departures through mid-December.

$899—BARCELONA: 5 NIGHTS WITH FLIGHTS
Explore Barcelona’s world-class museums and architectural masterpieces in the quieter winter months to pack more into your trip. You won’t waste hours in lines and can access top restaurants that are fully booked in summer. We save $300 on travel this January and February, when temperatures are still spring-like. Roundtrip flights from Toronto, hotel and daily breakfast are included.

$999—ST. KITTS GETAWAY FOR 2, REG. $2083
Most visitors to St. Kitts book months in advance, but when we pointed out that travel enthusiasts are more spontaneous, this resort gave us a terrific rate for stays this November and December. Spend four nights in Frigate Bay and get an upgraded Oceanview room, too.

Are you a travel enthusiast? Join the club today: https://travelzoo.com

Who are we?
We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travellers. Club Members receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel companies give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a modern travel enthusiast.

Media Contact: 
Amanda Ieraci – Toronto
+1 437 866 8540
aieraci@travelzoo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/club-offers-for-travel-enthusiasts-in-canada-302918543.html

SOURCE Travelzoo

Continue Reading

Technology

Howard Hughes Holdings Set to Join S&P SmallCap 600

Published

on

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 28. S&P 500 constituent CRH plc (NYSE: CRH) has acquired Arcosa in a deal that closed today, October 23.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name  

Action

Company Name

Ticker

GICS Sector

October 28, 2026

S&P SmallCap 600

Addition

Howard Hughes Holdings

HHH

Real Estate

October 28, 2026

S&P SmallCap 600

Deletion

Arcosa

ACA

Industrials

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. 

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

Media Inquiries
spdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/howard-hughes-holdings-set-to-join-sp-smallcap-600-302918511.html

SOURCE S&P Dow Jones Indices

Continue Reading

Technology

Chelsea FC announces multi-year sleeve partnership with Sokin, the business payments and FX platform

Published

on

By

Chelsea FC name fast-growing fintech platform as Principal Partner

LONDON, Oct. 23, 2026 /PRNewswire/ — Chelsea Football Club has today announced a multi-year partnership with Sokin, the embedded finance and payments company used by businesses worldwide. Sokin will be named a Principal Partner and Official Business Payments and FX Partner of Chelsea FC and Chelsea FC Women.

As a Principal Partner, Sokin will be represented on the sleeves of the Chelsea FC men’s, women’s and academy home, away, and third kits from the 2026/27 season.

The partnership brings together two ambitious London-headquartered organisations with worldwide reach – a club with millions of fans across the world and a fintech platform through which businesses move more than $11 billion a year. A club of Chelsea’s scale works in many currencies every day, with partners, competitions and supporters around the world, and needs a financial partner built to handle that.

Sokin gives finance teams business payments, multi-currency accounts, foreign exchange, checkout and treasury in one place, so they spend less time juggling banks and providers and keep more of what they move.

As Official Business Payments and FX Partner, Sokin will simplify how Chelsea FC sends, receives and manages money in the currencies the club operates in.

The Sokin logo will feature on the sleeve of the Chelsea shirt for the first time [when the men’s team host Tottenham Hotspur at Stamford Bridge on Saturday 24th October.]

Jason Gannon, President at Chelsea FC said:

“At Chelsea, we seek to partner with organisations that share our ambition and innovative mindset. Sokin’s expertise in business payments, and their focus on making both simpler for the businesses they serve, makes them a natural fit for the Club. We are pleased to welcome Sokin to the Chelsea family and look forward to working together in the years ahead.”

Vroon Modgill, CEO and founder at Sokin said:

“Chelsea plays on the biggest stage in world football, and its business runs in dozens of currencies. Sokin was built for that with regulated, multi-currency payments and foreign exchange for organisations that operate internationally. We’re proud to be the platform behind the business payments and FX of one of the most iconic teams in football. Sokin’s platform serves businesses in more than 170 countries. We’re thrilled to be partners for the season ahead. An organisation as sophisticated as Chelsea doesn’t leave its finances to chance.”

About Sokin

Sokin is the financial layer global business runs on. Businesses can transact, convert and hold money in 70+ currencies across 170+ countries. Some businesses use Sokin to manage global finance in-house. Others build it into their products to power financial experiences for their customers. Businesses move more than $9 billion a year on licenses Sokin holds in 36+ countries and infrastructure Sokin owns. Founded in 2019, Sokin has raised over $100 million from investors including Morgan Stanley Expansion Capital and Prysm Capital.

About Chelsea Football Club

Chelsea Football Club is one of the biggest, most successful football clubs globally and our men’s team are reigning world champions, having won the four-yearly FIFA Club World Cup in 2025. Our women’s team, Chelsea Women, are also multiple trophy winners.

Founded in 1905, Chelsea is London’s most central football club, based at the iconic 40,000-capacity Stamford Bridge stadium. Nicknamed the Blues, the club lifted the Champions League for the first time in 2012 and domestically has won the Premier League five times, the FA Cup eight times, the Football League Cup five times and the Football League Championship once, in 1955.

The Chelsea Women’s team have enjoyed a huge amount of success and in 2025 won the FA Women’s Super League for a sixth consecutive year and the eighth time overall. The Women’s FA Cup has been won on six occasions. We have also captured the FA Women’s League Cup four times as well as reaching the UEFA Women’s Champions League final in 2021. In two seasons, 2020/21 and 2024/25, a domestic treble of trophies was secured.

The Chelsea Foundation boasts one of the most extensive community initiatives in sport, helping to improve the lives of children and young people all over the world.

Media Contacts:

Taina Biggs
taina.biggs@sokin.com 

Nerissa Chesterfield
nerissa.chesterfield@chelseafc.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/chelsea-fc-announces-multi-year-sleeve-partnership-with-sokin-the-business-payments-and-fx-platform-302918466.html

Continue Reading

Trending